NXS Share Price Performance
AU$0.14
0.07 (107.14%)
46.1% undervalued intrinsic discount
AU$0.27
Fair Value
Price AU$0.14
AnalystConsensusTarget AU$0.27
Fair ValueAU$0.27
Share Pricen/a
Analysis Article • Jul 17
Next Science Limited Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
NXS Community Narratives
AN
Fair Value
·Fair Value AU$0.27 46.1% undervalued intrinsic discount
FDA Engagement And XPERIENCE Will Secure Future Confidence
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
FDA Engagement And XPERIENCE Will Secure Future Confidence
Key Takeaways Strong growth in key products and a high gross margin suggest potential for future revenue and net margin improvement. Addressing the FDA warning could enhance market confidence and stability, benefiting future earnings and stock valuation.Read more
AN
AU$0.27
46.1% undervalued intrinsic discount
Fair Value
Profit Margin
9.41%
Future PE
9.76x
Price in 2028
AU$0.33
Trending Discussion
Recently Updated Narratives
AN
FDA Engagement And XPERIENCE Will Secure Future Confidence
Fair Value: AU$0.27 46.1% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Next Science Limited Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -0.032
- 82.48%
- -42.74%
- -849.6%
About NXS
- Founded
- 2012
- Employees
- n/a
- CEO
- WebsiteView website
Next Science Limited engages in the research, development, and commercialization of technologies that resolve the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial wound Gel; acne gel; oral rinse; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds. The company was founded in 2012 and is headquartered in Sydney, Australia.
